Loading…
Loading…
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - QScreen AI Inc. (CSE: QAI) (OTC: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") today announced completion of the tiered screening architecture at the core of its commercialization strategy. The architecture is fully implemented in the Company's browser-based platform and is now being demonstrated to prospective institutional partners through the Company's US channel process, where a first signed evaluation agreement remains the stated near-term milestone.
Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") now holds two granted US patents covering its core impairment-detection method, after the United States Patent and Trademark Office granted the Company US Patent No. 12,640,164, "Systems and Methods for Detecting Impairment of an Individual," on May 26, 2026.
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators (CSA), the pilot program under CBO 51-933 allows eligible venture issuers to voluntarily transition from quarterly to semi-annual financial reporting.
Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement. The Company is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement through the issuance of 4,876,400 units (the "Units") at a price of $0.05 per Unit for gross proceeds of approximately $243,820.
NYLI Hedge Multi-Strategy Tracker ETF (QAI) aims to replicate hedge fund performance but falls short in both construction and returns. QAI's top holdings are heavily weighted toward floating-rate bonds and European equities, diverging from typical hedge fund strategy allocations. QAI's 5-year CAGR of 2.5% and Sharpe ratio of 0.40 underperform both the equal-weight S&P 500 and peer multi-strategy ETFs.
Toronto, Ontario--(Newsfile Corp. - June 1, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, today announced that members of its senior leadership team will participate in a five-city investor roadshow across Central Europe from June 1 to June 5, 2026. Date City June 1 Munich, Germany June 2 Ljubljana, Slovenia June 3 Budapest, Hungary June 4 Bratislava, Slovakia June 5 Vienna, Austria Advancing Platform Development and Strategic Reach Over recent months, QScreen has continued to expand both its technology platform and strategic advisory network.
Individual voice baseline established on first encounter, deviation measured on every return visit; no additional hardware required; platform now fully integrated across all three signal modalities Toronto, Ontario--(Newsfile Corp. - May 6, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen"), today announced the full integration of a novel voice analysis engine into its multi-signal screening platform, expanding the system from camera and structured clinical intake into a three-modality real-time screening solution. QScreen now assesses physiological, acoustic and behavioral indicators simultaneously during the same intake workflow using existing microphones already present on standard assessment devices.
Nine instruments validated against published standards including Columbia C-SSRS, CIWA-Ar, and COWS; paper-only workflow showed materially lower detection rates across the same scenarios; 60-day live pilot structured and ready Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening today reports internal validation results for its correctional intake platform across 65 calibrated clinical scenarios tested against published instrument thresholds. By digitizing the high-liability blind spots of correctional intake, QAI transforms a universal institutional risk into a scalable SaaS revenue model with zero-hardware deployment friction.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for QAI and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.